In September HGS disclosed that its wound-healing agent, repifermin, had failed to heal venous ulcers in a trial of 352 patients.
FORBES: Beyond Talk
2.
Now repifermin is being tested for preventing chemotherapy's side effects, but the market is modest, and HGS faces competition from industry giant Amgen.